Medicare Enrolled
Dr. Mitchell Klavans, M.D.
Optician · Largo, FL
Practice pattern: Clinical Cardiology— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Klavans from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Klavans? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Klavans
Dr. Mitchell Klavans is an optician in Largo, FL, with 19 years in practice. Based on federal Medicare data, Dr. Klavans performed 11,353 Medicare services across 6,159 unique beneficiaries.
Between the years covered by Open Payments, Dr. Klavans received a total of $4,009 from 46 pharmaceutical and/or device companies across 194 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in optician. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Klavans is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice▲ Top 8% volume in FL$ $4,009 industry payments
Medicare Practice Summary
Medicare Utilization ↗11,353
Medicare services
Top 8% in FL for optician
6,159
Unique beneficiaries
$48
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~598 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Automated urinalysis | 2,407 | $2 | $5 |
| Botox injection, per unit | 2,400 | $5 | $12 |
| Office visit, established patient (30-39 min) | 1,549 | $91 | $321 |
| Office visit, established patient (20-29 min) | 1,022 | $65 | $227 |
| Blood draw (venipuncture) | 338 | $6 | $6 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 324 | $135 | $370 |
| Diagnostic exam of bladder and urethra using an endoscope | 279 | $180 | $602 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 262 | $29 | $163 |
| Chronic care management, first 20 min/month | 241 | $49 | $159 |
| Insertion of lower leg neurostimulator electrode | 229 | $87 | $304 |
| Electronic assessment of bladder emptying | 213 | $6 | $36 |
| Bladder ultrasound after voiding | 211 | $8 | $26 |
| New patient office visit (45-59 min) | 182 | $120 | $422 |
| Limited ultrasound scan behind abdominal cavity | 138 | $37 | $117 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 134 | $294 | $976 |
| Insertion of device into abdomen with pressure and urine flow rate study | 132 | $150 | $478 |
| Drug injection, under skin or into muscle | 130 | $11 | $35 |
| Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | 106 | $18 | $57 |
| Other procedure on male genital system | 101 | $141 | $1,000 |
| Injection, garamycin, gentamicin, up to 80 mg | 93 | $2 | $3 |
| Instillation of anti-cancer drug into bladder | 64 | $69 | $219 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 62 | $26 | $81 |
| Test or measurement for functional capacity, each 15 minutes | 60 | $27 | $84 |
| Application of electrical stimulation with therapist present, each 15 minutes | 57 | $11 | $37 |
| Ultrasound scan of pelvic region through rectum | 54 | $99 | $322 |
| Biopsy of prostate gland | 45 | $192 | $616 |
| Simple change of bladder tube | 41 | $68 | $243 |
| Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | 40 | $66 | $256 |
| Complete ultrasound scan of pelvis | 39 | $74 | $213 |
| Hospital follow-up visit, low complexity | 34 | $41 | $98 |
| Office visit, established patient, complex (40-54 min) | 32 | $143 | $454 |
| Simple insertion of temporary bladder tube | 31 | $49 | $156 |
| Biofeedback training for bowel or bladder control, initial 15 minutes | 29 | $61 | $201 |
| Biofeedback training for bowel or bladder control, each additional 15 minutes | 29 | $25 | $81 |
| Insertion of stent in ureter using an endoscope | 28 | $85 | $397 |
| Biopsy of bladder using an endoscope | 27 | $75 | $361 |
| Electronic analysis of implanted neurostimulator generator with complex spinal cord or peripheral nerve stimulator programming | 27 | $44 | $142 |
| Insertion of tube into ureter using an endoscope through bladder area | 25 | $49 | $337 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 2.0-5.0 cm | 23 | $220 | $737 |
| Study of rectum sensitivity and function | 23 | $215 | $679 |
| Hospital follow-up visit, moderate complexity | 23 | $64 | $179 |
| Exam with injections of chemical for destruction of bladder using an endoscope | 18 | $299 | $984 |
| Telephone medical discussion with physician, 5-10 minutes | 15 | $30 | $114 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 0.5-2.0 cm | 13 | $186 | $629 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 12 | $588 | $1,867 |
| Complete laser vaporization of prostate including control of bleeding using an endoscope | 11 | $554 | $1,774 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
0.2% high complexity
28.3% medium
71.4% routine
Industry Payment Transparency
Open Payments through 2024 ↗$4,009
Total received (2018-2024)
Avg $573/year across 7 years
Top 26% in FL for optician
46
Companies
194
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$3,561 (88.8%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$448 (11.2%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$507
2023$1,156
2022$662
2021$481
2020$219
2019$474
2018$510
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Astellas Pharma US Inc
$734
Janssen Biotech, Inc.
$406
Myriad Genetic Laboratories, Inc.
$242
Dendreon Pharmaceuticals LLC
$233
Sumitomo Pharma America, Inc.
$199
Boston Scientific Corporation
$171
Merck Sharp & Dohme LLC
$147
TOLMAR Pharmaceuticals, Inc.
$135
Augmenix, Inc.
$115
Novartis Pharmaceuticals Corporation
$114
COLOPLAST CORP
$89
BOSTON SCIENTIFIC CORPORATION
$87
ABBVIE INC.
$81
Axonics, Inc.
$81
Endo Pharmaceuticals Inc.
$77
PFIZER INC.
$75
Ferring Pharmaceuticals Inc.
$71
Laborie Medical Technologies Corp.
$68
Coloplast Corp
$67
Amgen Inc.
$65
AbbVie, Inc.
$64
UroGen Pharma, Inc.
$63
Acerus Pharmaceuticals Corporation
$54
Bayer Healthcare Pharmaceuticals Inc.
$54
Myovant Sciences Inc.
$50
Bayer HealthCare Pharmaceuticals Inc.
$47
UROVANT SCIENCES INC
$42
Blue Earth Diagnostics Limited
$39
Mission Pharmacal Company
$36
AbbVie Inc.
$25
Progenics Pharmaceuticals, Inc.
$24
Telix Pharmaceuticals
$22
Tolmar, Inc.
$22
Endo USA, Inc.
$20
Medtronic, Inc.
$20
Calyxo, Inc.
$20
PROGENICS PHARMACEUTICALS, INC.
$19
Caldera Medical, Inc
$17
AstraZeneca Pharmaceuticals LP
$17
IMMUNITYBIO, INC.
$16
Sun Pharmaceutical Industries Inc.
$15
UROGEN PHARMA, INC.
$15
Shionogi Inc
$14
Allergan, Inc.
$13
AngioDynamics, Inc.
$12
Ambu Inc.
$10
Top 3 companies account for 34.5% of total payments
Associated products mentioned in payments ›
ADSTILADRIN · AMS · AMS 700 CXR RTE KIT · ANKTIVA · Androgel · Axonics · Axumin · BOTOX · BRAC CDx · CVAC ASPIRATION SYSTEM · Desara · ELIGARD · ERLEADA · FIRMAGON · Fetroja · GEMTESA · GENERAL BPH · GENERAL KIDNEY STONE DISEASE · GENERAL THERAPIES · GENERAL BPH · GENERAL KIDNEY STONE DISEASE · ILLUCCIX · JELMYTO · KEYTRUDA · LUPRON DEPOT · LYNPARZA · Lupron · Lupron Depot · MYRBETRIQ · Myrbetriq · NANOKNIFE · Natesto · Nubeqa · ODOMZO (sonidegib) capsules · ORGOVYX · PLUVICTO · PROLARIS · PROVENGE · PYLARIFY · Prolaris · SONICISION · SPEEDICATH · SUTENT · SpaceOAR · SpaceOAR VUE System - 10mL · SpeediCath · TITAN · Uribel · Urocit-K · XGEVA · XIAFLEX · XTANDI · Xtandi
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (89%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $35 per 100 Medicare services performed
Geographic Context
Opticians within 10 mi
464
Per 100K population
48.3
County median income
$70,293
Nearest hospital
WINDMOOR HEALTHCARE OF CLEARWATER
2.4 mi
2.4 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Klavans is a clinical cardiology specialist, with above-average Medicare volume (top 8% in FL), and low-engagement industry engagement, with 19 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Klavans experienced with automated urinalysis?
Based on Medicare claims data, Dr. Klavans performed 2,407 automated urinalysis services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Klavans receive payments from pharmaceutical companies?
Yes. Dr. Klavans received a total of $4,009 from 46 companies across 194 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Klavans's costs compare to other opticians in Largo?
Dr. Klavans's average Medicare payment per service is $48. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Klavans) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Opticians in Largo
Browse opticians in Largo ranked by procedure volume and transparency data.
Highest volume
Top Opticians in FL
Opticians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Opticians in FL
Which FL opticians receive the most from drug and device companies.
By company
Astellas Pharma US Inc Payments to Doctors
See all physicians who received payments from Astellas Pharma US Inc.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc..
By company
Myriad Genetic Laboratories, Inc. Payments to Doctors
See all physicians who received payments from Myriad Genetic Laboratories, Inc..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology